NCT06954142 Restricted Versus Liberal Fluid Intake for Prevention of Bronchopulmonary Dysplasia
| NCT ID | NCT06954142 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Children's Hospital Basel |
| Condition | Bronchopulmonary Dysplasia |
| Study Type | INTERVENTIONAL |
| Enrollment | 750 participants |
| Start Date | 2025-07-12 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 750 participants in total. It began in 2025-07-12 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to determine whether restricted fluid intake (135 ±5 mL/kg/day) compared to liberal fluid intake (165 ±5 mL/kg/day) from day 8 of life reduces the incidence of bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age or prior death in preterm infants born \<30 weeks gestational age.
Eligibility Criteria
Inclusion Criteria: * Hospitalised preterm infants born before 30 weeks 0 days gestation * Signed informed consent for further research use of health-related data Exclusion Criteria: * congenital malformations * diseases likely to affect life expectancy, lung function, fluid strategy, or neurodevelopment * renal disease requiring fluid management outside the clinical standard of care * congenital heart disease not including patent ductus arteriosus (PDA)
Contact & Investigator
Sven Schulzke, Prof.MD
PRINCIPAL INVESTIGATOR
University Children's Hospital Basel
Frequently Asked Questions
Who can join the NCT06954142 clinical trial?
This trial is open to participants of all sexes, aged 8 Days or older, studying Bronchopulmonary Dysplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06954142 currently recruiting?
Yes, NCT06954142 is actively recruiting participants. Contact the research team at anne.carrer@ukbb.ch for enrollment information.
Where is the NCT06954142 trial being conducted?
This trial is being conducted at Aarau, Switzerland, Basel, Switzerland, Bern, Switzerland, Chur, Switzerland and 5 additional locations.
Who is sponsoring the NCT06954142 clinical trial?
NCT06954142 is sponsored by University Children's Hospital Basel. The principal investigator is Sven Schulzke, Prof.MD at University Children's Hospital Basel. The trial plans to enroll 750 participants.